Zacks Investment Research
15 Jul 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The mean analyst price target for Cytokinetics (CYTK) is $106.95, representing a 30.5% potential upside from its last close of $81.93. — A significant gap between current price and consensus target typically attracts bullish investor interest.
+0.40Analysts are showing strong agreement regarding Cytokinetics' ability to report better earnings than previously predicted. — Positive earnings estimate revisions are a strong leading indicator of stock price appreciation.
+0.30Which stocks this story touches
The company shows strong upside potential with a mean analyst price target of $106.95 and positive earnings estimate revisions.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
